Justin Byers, Founder & CEO of Axio BioPharma
- Science and instruments have continued to improve, but information sharing between teams remains broken.
- Data transfers between organizations often lead to the loss of context, slowing progress.
Podcast
Podcast: Play in new window | Download
Follow TBCY RSS
Overview
In this episode of The Brand Called You, the conversation focused on the intricate data challenges facing the biopharma industry and how Axio BioPharma is working to transform process data connectivity and AI readiness. The discussion explored how experience in both biotechnology and cybersecurity is shaping new solutions that make critical manufacturing data more accessible, trustworthy, and actionable for the pharmaceutical industry.
00:47-What did industry experience reveal about the true bottleneck in biopharma?
- Science and instruments have continued to improve, but information sharing between teams remains broken.
- Data transfers between organizations often lead to the loss of context, slowing progress.
- The real bottleneck is the data layer, not the science itself.
- This unmet challenge inspired Axio BioPharma’s mission.
02:07-How did blending biotech and cybersecurity expertise influence Axio’s design?
- The team combined bioinformatics and IT security perspectives.
- Recognized that AI models rely on high-quality, well-integrated data.
- Adopted a federated, secure framework inspired by cybersecurity platforms, tailored specifically for pharma.
- Ensured that companies’ proprietary data remains protected while enabling interoperability.
04:56-Why is fragmented process data such a massive problem in biomanufacturing?
- Biomanufacturing relies on dozens of software systems, each with isolated data.
- These systems do not communicate, making it difficult to gain a complete operational view.
- Axio connects these silos by providing a unified interface and a common “data language” without creating massive, unmanageable data lakes.
- The goal is faster collaboration and more comprehensive process insights.
07:10-What does it mean for Axio to be a “coordination layer” for AI rather than building AI models?
- The value lies in making structured, high-quality data accessible to existing AI models.
- Many pharmaceutical companies already have sophisticated AI models but lack the quality and quantity of data required for optimal performance.
- Axio focuses on integrating fragmented systems so data becomes AI-ready.
08:57-Why is vendor neutrality crucial for Axio’s platform—and how is it achieved?
- Neutrality ensures that Axio is trusted by both pharmaceutical companies and contract manufacturers.
- The platform does not favor any equipment vendor or manufacturing partner.
- Large manufacturers attempting similar solutions struggle to maintain this level of impartiality, creating trust concerns.
- Axio deliberately stays out of manufacturing, preserving its independence and neutrality.
12:45-What are the biggest misunderstandings about AI readiness in pharma?
- Many believe that having the right AI model or team is enough.
- The biggest obstacle is poor, fragmented, or incomplete data.
- True AI readiness begins with comprehensive, well-contextualized, and comparable data.
14:25-How will improved data coordination impact process development and manufacturing?
- AI will drive significant improvements once it is powered by structured, high-quality data.
- Areas such as process scale-up and root-cause analysis of manufacturing deviations stand to benefit greatly.
- Proactive, real-time monitoring with AI could identify process issues before they occur, saving both time and money.
16:28-How difficult is it technically to standardize data across enterprise systems?
- The challenge is immense because of the diversity of systems, sites, and vendors.
- Every enterprise, manufacturing site, and partnership typically has its own unique IT environment.
- Solving this requires robust “translation layers” so information can be seamlessly understood and compared, regardless of its source.
18:18-Will biomanufacturing data networks evolve like those in finance or IT?
- The expectation is yes—biomanufacturing will eventually adopt neutral, shared data pipelines.
- These pipelines will enable secure, routine, and efficient information exchange between sponsors, manufacturers, and partners, much like financial transactions or cybersecurity networks.
RESOURCES:
Learn more about Justin Byers: LinkedIn
Enjoyed this podcast?
The discussion explored why biomanufacturing has become so complex: dozens of specialized systems that do not communicate with one another. Imagine trying to solve a puzzle in which every team holds a different piece, but no one has the complete picture.
Share your thoughts in the comments and help spread these insights throughout your network
Would you love to give us 5 stars? ⭐⭐⭐⭐⭐ If yes, we’d greatly appreciate your review. Help us reach more people as we bring conversations with leaders, high achievers, and thought leaders from diverse backgrounds and nationalities. Excellence can come from anywhere. Stay informed and hear from emerging achievers and experts from around the world.
Stay updated with what’s shaping the world today through the latest The Brand Called You Podcast episode. Follow us on iTunes, Spotify, and Anchor.fm.
You can find us at:
Website: www.tbcy.in
Instagram: http://bit.ly/3HO7N06
Facebook:http://bit.ly/3YzJOaD
Twitter: http://bit.ly/3wMBOXK
LinkedIn: https://www.linkedin.com/company/tbcy/
YouTube: http://bit.ly/3jmBqfq
Chingari: https://chingari.io/tbcypodcast
Josh: http://bit.ly/3WWP0nB
Thanks for listening!
Profile
- Biopharma technology leader brings expertise across biotechnology, cybersecurity, and digital transformation to solve complex challenges in pharmaceutical manufacturing.
- Through Axio BioPharma, they are advancing process data connectivity to make manufacturing information more accessible, secure, and interoperable.
- Their work focuses on preparing biopharma organizations for AI by improving data quality, trust, and integration across manufacturing systems.
